These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 24347238)

  • 21. Downstream processing of virus-like particles: single-stage and multi-stage aqueous two-phase extraction.
    Ladd Effio C; Wenger L; Ötes O; Oelmeier SA; Kneusel R; Hubbuch J
    J Chromatogr A; 2015 Feb; 1383():35-46. PubMed ID: 25637013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthetic biology design to display an 18 kDa rotavirus large antigen on a modular virus-like particle.
    Lua LH; Fan Y; Chang C; Connors NK; Middelberg AP
    Vaccine; 2015 Nov; 33(44):5937-44. PubMed ID: 26387437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epitope engineering and molecular metrics of immunogenicity: a computational approach to VLP-based vaccine design.
    Joshi H; Lewis K; Singharoy A; Ortoleva PJ
    Vaccine; 2013 Oct; 31(42):4841-7. PubMed ID: 23933338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virus-like particles in picornavirus vaccine development.
    Dong H; Guo HC; Sun SQ
    Appl Microbiol Biotechnol; 2014 May; 98(10):4321-9. PubMed ID: 24647496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures.
    Pushko P; Pumpens P; Grens E
    Intervirology; 2013; 56(3):141-65. PubMed ID: 23594863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-throughput process development of an alternative platform for the production of virus-like particles in Escherichia coli.
    Ladd Effio C; Baumann P; Weigel C; Vormittag P; Middelberg A; Hubbuch J
    J Biotechnol; 2016 Feb; 219():7-19. PubMed ID: 26707548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-throughput characterization of virus-like particles by interlaced size-exclusion chromatography.
    Ladd Effio C; Oelmeier SA; Hubbuch J
    Vaccine; 2016 Mar; 34(10):1259-67. PubMed ID: 26845741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessing stability and assembly of the hepatitis B surface antigen into virus-like particles during down-stream processing.
    Zahid M; Lünsdorf H; Rinas U
    Vaccine; 2015 Jul; 33(31):3739-45. PubMed ID: 26079614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virus-like particles as powerful vaccination strategy against human viruses.
    Hadj Hassine I; Ben M'hadheb M; Almalki MA; Gharbi J
    Rev Med Virol; 2024 Jan; 34(1):e2498. PubMed ID: 38116958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Developments in virus-like particle-based vaccines for HIV.
    Buonaguro L; Tagliamonte M; Visciano ML; Tornesello ML; Buonaguro FM
    Expert Rev Vaccines; 2013 Feb; 12(2):119-27. PubMed ID: 23414404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bluetongue virus serotype 8 virus-like particles protect sheep against virulent virus infection as a single or multi-serotype cocktail immunogen.
    Stewart M; Dubois E; Sailleau C; Bréard E; Viarouge C; Desprat A; Thiéry R; Zientara S; Roy P
    Vaccine; 2013 Jan; 31(3):553-8. PubMed ID: 23159460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular energetics in the capsomere of virus-like particle revealed by molecular dynamics simulations.
    Zhang L; Tang R; Bai S; Connors NK; Lua LH; Chuan YP; Middelberg AP; Sun Y
    J Phys Chem B; 2013 May; 117(18):5411-21. PubMed ID: 23586433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Virus-like particle-based vaccines against hepatitis C virus infection.
    Bellier B; Klatzmann D
    Expert Rev Vaccines; 2013 Feb; 12(2):143-54. PubMed ID: 23414406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitivity of immune response quality to influenza helix 190 antigen structure displayed on a modular virus-like particle.
    Anggraeni MR; Connors NK; Wu Y; Chuan YP; Lua LH; Middelberg AP
    Vaccine; 2013 Sep; 31(40):4428-35. PubMed ID: 23845811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines.
    Middelberg AP; Rivera-Hernandez T; Wibowo N; Lua LH; Fan Y; Magor G; Chang C; Chuan YP; Good MF; Batzloff MR
    Vaccine; 2011 Sep; 29(41):7154-62. PubMed ID: 21651936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Virus-Like Particles as an Instrument of Vaccine Production].
    Syomin BV; Ilyin YV
    Mol Biol (Mosk); 2019; 53(3):367-379. PubMed ID: 31184601
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Affinity chromatography for virus-like particle manufacturing: Challenges, solutions, and perspectives.
    Ma J; Tian Z; Shi Q; Dong X; Sun Y
    J Chromatogr A; 2024 Apr; 1721():464851. PubMed ID: 38574547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New Routes and Opportunities for Modular Construction of Particulate Vaccines: Stick, Click, and Glue.
    Brune KD; Howarth M
    Front Immunol; 2018; 9():1432. PubMed ID: 29997617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development.
    Wu PC; Lin WL; Wu CM; Chi JN; Chien MS; Huang C
    Appl Microbiol Biotechnol; 2012 Sep; 95(6):1501-7. PubMed ID: 22526782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.